- Home
- HL vs EXEL Comparison
HL vs EXEL Comparison
Compare HL & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HL | EXEL |
|---|---|---|
| Founded | 1891 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3B | 12.7B |
| IPO Year | 2002 | 2000 |
Fundamental Metrics
Financial Performance| Metric | HL | EXEL |
|---|---|---|
| Price | $18.27 | $51.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 21 |
| Target Price | $21.13 | ★ $46.50 |
| AVG Volume (30 Days) | ★ 41.2M | 2.6M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.09% | N/A |
| EPS Growth | ★ 716.67 | 57.95 |
| EPS | 0.15 | ★ 1.60 |
| Revenue | ★ $645,957,000.00 | $452,477,000.00 |
| Revenue This Year | $4.92 | $13.61 |
| Revenue Next Year | N/A | $13.13 |
| P/E Ratio | $122.47 | ★ $32.03 |
| Revenue Growth | ★ 45.63 | N/A |
| 52 Week Low | $7.40 | $33.76 |
| 52 Week High | $34.17 | $57.57 |
Technical Indicators
Market Signals| Indicator | HL | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 65.46 | 40.73 |
| Support Level | $16.46 | $50.80 |
| Resistance Level | $20.97 | $52.84 |
| Average True Range (ATR) | 0.78 | 1.95 |
| MACD | 0.38 | -0.61 |
| Stochastic Oscillator | 91.29 | 15.63 |
Price Performance
Historical ComparisonAbout HL Hecla Mining Company
Hecla Mining Co produces and explores silver, gold, zinc, and other metals. The operating business segments are Greens Creek, Lucky Friday, Keno Hill, and Casa Berardi. It generates maximum revenue from the Greens Creek segment. Geographically, It operates in Canada, the United States, and Mexico, and it derives a majority of its revenue from the United States.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.